BillionToOne, Inc. BLLN
BillionToOne, Inc. (Nasdaq: BLLN) is a diagnostics company. Its next catalyst on record is tissue-free pan-cancer MRD test: commercial launch (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tissue-free pan-cancer MRD test — commercial launch (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| UNITY (prenatal sgNIPT, carrier, aneuploidy, fetal antigen tests) | prenatal screening | — | NA_NON_THERAPEUTIC |
| Northstar Select / Northstar Response | pan-cancer liquid biopsy | — | NA_NON_THERAPEUTIC |
| tissue-free pan-cancer MRD test | minimal residual disease detection | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.